^
    Back
    Association details:
    Biomarker:MGMT underexpression
    Cancer:Pituitary Gland Carcinoma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Endocrinol Metab
    Title:

    Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide

    Published date:
    01/01/2021
    Excerpt:
    We report on 24 patients with aggressive pituitary tumors...treated with TMZ...Median MGMT staining was 9% (5–20%) in responders vs 93% (50–100%) in nonresponders....The data suggest that tumoral MGMT staining below 50% is associated with a high likelihood of treatment response.
    DOI:
    10.1210/jc.2014-4350
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Eur J Endocrinol
    Title:

    Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016

    Excerpt:
    Tumours with low MGMT expression often achieved regression during TMZ treatment, 19/41 (46%), whereas tumours with high MGMT expression more often showed no response (13/17, 76%) (Fig. 5). A complete response (CR) was only seen among tumours with low MGMT expression.
    DOI:
    10.1530/EJE-17-0933